Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031


Watson Pharmaceuticals, Inc. : Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

05/04/2012 | 04:05pm US/Eastern

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at The webcast can also be accessed at the following URL:

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

    CONTACTS:                         Investors:
                                      Lisa DeFrancesco
                                      (862) 261-7152

                                      Charlie Mayr
                                      (862) 261-8030


SOURCE Watson Pharmaceuticals, Inc.

Recommend :
React to this article
Latest news on ACTAVIS INC
1h ago AstraZeneca buys Almirall lung drugs for up to $2.1 billion
2d ago Pfizer's need for deal looms larger with earnings report
07/21 ACTAVIS : Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for..
07/21 ACTAVIS : Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for..
07/14DJU.S. HOT STOCKS : Hot Stocks to Watch
07/11 ACTAVIS : Confirms Generic Diclegis® Patent Challenge
07/08 ACTAVIS : Confirms Generic Ampyra® Patent Challenge
07/02 ACTAVIS : Impax Acquires Two Products from Actavis
07/02 ACTAVIS : Announces Final Stockholder Merger Consideration Election Results in C..
07/01 ACTAVIS : Completes Forest Laboratories Acquisition
Dynamic quotes